### Patient Preference for the Port Delivery System With Ranibizumab vs Intravitreal Injections: 1-Year Results From the Phase 3 Pagoda Trial in Patients With Diabetic Macular Edema

### Adrian Koh, MD, FRCS<sup>1</sup>

Margaret A. Chang, MD, MS<sup>2</sup>; Dennis M. Marcus, MD<sup>3</sup>; Kira Baldonado, MPH<sup>4</sup>; Avril Daly<sup>5</sup>; and Kailin Tian, MD, PhD<sup>6</sup>

<sup>1</sup> Eye & Retina Surgeons, Camden Medical Centre, Singapore, Republic of Singapore

<sup>2</sup> Retinal Consultants Medical Group, Sacramento, CA

<sup>3</sup> Southeast Retina Center and Medical College of Georgia, Augusta, GA

<sup>4</sup> Public Health and Policy at Prevent Blindness, Chicago, IL

<sup>5</sup> Retina International, Dublin, Ireland

<sup>6</sup> F. Hoffmann-La Roche AG, Basel, Switzerland

Presented at the 17th Congress of the Asia-Pacific Vitreo-Retina Society | Singapore | November 22–24, 2024

#### **Disclosures**

#### **Financial Disclosures**

- AK: Consultant: Allergan, Bayer, Heidelberg Engineering, Novartis, ZEISS
- MAC: Consultant: Genentech, Inc./Roche, Iveric Bio, Regenxbio; Grant/Research Support: Alexion, EyeBio, Mylan, NGM Bio, Novartis, OcuTerra, Opthea
- DMM: Consultant: Clearside, Coherus, Genentech, Inc./Roche, Regeneron, Regenxbio, Vantage, Vial; Research Grants: Alcon, Alexion, Allergan, Amgen, Annexon, Apellis, Boehringer Ingelheim, Chengdu Kanghong, Clearside, Gemini, Genentech, Inc., Graybug, Gyroscope, Hengenix, Ionis, Iveric Bio, KalVista, Kodiak Sciences, Mylan, Novartis, Oculis, Opthea, Optos, Outlook, Oxurion, Regeneron, Regenxbio, Rezolute, Roche, Samsung, Stealth BioTherapeutics, Topcon, Xplore, ZEISS
- KB, AD: None
- KT: Employment and Stocks/Stock Options: F. Hoffmann-La Roche AG

#### **Study and Product Disclosures**

- The Port Delivery System with ranibizumab (PDS) has been approved by the US Food and Drug Administration for the treatment of nAMD in adults who have previously responded to
   ≥ 2 anti-VEGF injections. Please note that the PDS has not been approved for use outside of the United States
- The US Food and Drug Administration has issued a boxed warning for the PDS because it has been associated with a 3-fold higher rate of endophthalmitis compared with monthly intravitreal injections of ranibizumab<sup>1</sup>
- This study includes research conducted on human subjects
- Institutional Review Board approval was obtained prior to study initiation
- Funding was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland, for the study and third-party writing assistance, which was provided by Nibedita Gupta, PhD, CMPP, of Envision Pharma Group

# Port Delivery System With Ranibizumab (PDS) Is an Innovative Drug–Device Combination for Continuous Drug Delivery




Implant

Refill Needle



- Refillable ocular implant for **continuous delivery** of a customized formulation of ranibizumab 100 mg/mL
  - In-clinic refill-exchange procedures 1 or 2 times a year
- Designed to maintain clinical benefits of monthly intravitreal anti-VEGF therapy while reducing treatment burden of retinal diseases
  - In Archway, PDS was noninferior to monthly intravitreal ranibizumab injections in nAMD
  - Real-world outcomes in DME reduced due to undertreatment
- The patient voice is becoming increasingly important for informing clinical decisions
- Patient preference for PDS vs intravitreal injections was evaluated in the Pagoda trial for DME

# The Phase 3 Pagoda Trial Evaluated the Efficacy and Safety of PDS Q24W in DME



Ċ

**Pagoda met primary endpoint:** PDS Q24W was **noninferior** to monthly ranibizumab in BCVA change from baseline averaged over weeks 60/64, with adjusted mean (95% CI) BCVA change of +9.6 (8.7–10.5) letters in the PDS Q24W arm vs +9.4 (8.3–10.5) letters in the monthly ranibizumab arm

Pagoda clinical trial [NCT04108156]. <sup>a</sup> Delayed PDS implantation and initial fill, if applicable. <sup>b</sup> Patients were treatment naïve for DR with or without DME in the study eye or previously treated, as long as no treatment was administered in the study eye up to 6 months before randomization. <sup>c</sup> If week 16 (PDS Q24W arm) or week 64 (ranibizumab 0.5 mg Q4W arm) is not possible, additional loading dose required at week 16 or week 64; implant insertion procedure must happen within 28 ± 7 days since last intravitreal injection; additional visits for safety assessments 1 and 7 days after implantation. <sup>d</sup> Patients were assessed for the need for supplemental intravitreal ranibizumab 0.5 mg treatment at study visits 16 and 20 weeks after implant insertion or each completed refill-exchange procedure. BCVA, best-corrected visual acuity; CI, confidence interval; CI-DME, center-involved diabetic retinopathy with diabetic macular edema; D, day; DME, diabetic macular edema; DR, diabetic retinopathy; PDS, Port Delivery System with ranibizumab; Q4W, every 4 weeks; R, randomization.

#### **Baseline Demographics and Ocular Characteristics Were Generally** Well Balanced Across Study Arms

aracteristic	PDS 100 mg/mL Q24W (n = 381)	Intravitreal Ranibizumab 0.5 mg Q4W (n = 253)	Characteristic	PDS 100 mg/ml Q24W (n = 381)
Age, mean (SD)	60.9 (9.40)	60.2 (9.99)	BCVA letter score, mean (SD)	65.4 (11.3)
Male, n (%)	217 (57.0)	146 (57.7)	CST, mean (SD) (µm)	484.9 (133.2)
Ethnicity, n (%)			ETDRS-DRSS status, <sup>a</sup> n (%)	( , , , , , , , , , , , , , , , , , , ,
Hispanic or Latino	78 (20.5)	41 (16.2)		
Non-Hispanic or Latino	300 (78.7)	209 (82.6)	DRSS level ≤ 53 NPDR	354 (92.9)
Race, n (%)			DRSS level ≥ 60 PDR	20 (5.2)
White	289 (75.9)	200 (79.1)	Prior intravitreal anti-VEGF therapy for DR with/without	87 (22.8)
Black or African American	60 (15.7)	33 (13.0)	DME, n (%)	. ,

Pagoda clinical trial [NCT04108156]. Efficacy population.

<sup>a</sup> 7 patients in each arm had baseline DRSS unable to be graded, so totals do not add up to 100%.

BCVA, best-corrected visual acuity; CST, central subfield thickness; DME, diabetic macular edema; DR, diabetic retinopathy; DRSS, Diabetic Retinopathy Severity Scale; ETDRS, Early Treatment Diabetic Retinopathy Study; NPDR, nonproliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy; PCR, proliferative diabetic retinopathy; PCR, vascular endothelial growth factor.

### The PDS Patient Preference Questionnaire (PPPQ)


**PDS Patient Preference Questionnaire (PPPQ):** a 3-item questionnaire that captures a patient's **preference for treatment**, the **strength** of their preference, and the **reasons** for their preference<sup>1</sup>



(1)	Which method of adm	inistration did	l you prefer?			
$\smile$	Intravitreal injections	Port Deliver	ry System	No preference		
$\frown$						
(2)	If you have a preferen	ce for one of t	he administra	ation routes, how	strong is this prefe	erence?
$\smile$	Very strong	Fairly strong	g	Not very strong		
(3)	If you have a preferen Please choose all that		he administra	ation routes, what	t are the main reas	ons for your preference?
$\mathbf{}$	Less worry or nervousnes		Less disco	mfort	Other rea	ason
	Requires less time for tre		Fewer trea	tments		

႙႙ႍႄ


#### 82% of PDS Patients Preferred PDS Over Intravitreal Injections




Pagoda clinical trial [NCT04108156]. Percentages may not add up to 100 due to rounding up. <sup>a</sup> mITT population comprised of all patients in the in the efficacy population with the exclusion of all patients in the randomization blocks consisting of PDS patients noncompliant to the protocol-defined PDS insertion schedule due to sponsor-initiated surgery pause. <sup>b</sup> Of the 13 patients who preferred intravitreal injections, only 4 experienced adverse events (cataract, n = 4; conjunctival bleb, n = 1; vitreous hemorrhage, n = 1). Of these 4 patients, 3 were NPDR and 1 was PDR.

IVI, intravitreal; mITT, modified intent-to-treat; NPDR, nonproliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy; PDS, Port Delivery System with ranibizumab; PPPQ, PDS Patient Preference Questionnaire.

## Majority of Patients Preferred PDS Regardless of Injections Prior to Baseline



#### Majority of Patients Preferred PDS Regardless of the Number of Intravitreal Injections From Baseline Until Week 64



### **Ocular AESIs Were Well Understood and Manageable**

No Cases of Endophthalmitis or Retinal Detachment and 1 Case of Implant Dislocation Were Reported in the PDS Q24W Arm After Implantation Through Week 64

	PDS 100 mg/mL Q24W (n = 320) Overall		Intravitreal Ranibizumab 0.5 mg Q4W (n = 314) Overall	
Patient Incidence, % <sup>a</sup>				
	All	Serious	All	Serious
Total number of AE, n	110	12	34	2
Total number of patients with ≥ 1 AE, n (%)	88 (27.5)	9 (2.8)	28 (8.9)	2 (0.6)
Cataract <sup>b</sup>	35 (10.9)	1 (0.3)	23 (7.3)	1 (0.3)
Conjunctival bleb/conjunctival filtering bleb leak <sup>c</sup>	25 (7.8)	4 (1.3)	0	0
Conjunctival erosion	6 (1.9)	5 (1.6)	0	0
Conjunctival retraction	4 (1.3)	1 (0.3)	0	0
Implant dislocation <sup>d</sup>	1 (0.3)	1 (0.3)	0	0
Endophthalmitis	0	0	1 (0.3)	1 (0.3)
Hyphema	6 (1.9)	0	0	0
Retinal detachment <sup>e</sup>	0	0	0	0
Vitreous hemorrhage	31 (9.7)	1 (0.3)	5 (1.6)	0


#### Ocular AESIs in the Study Eye Through Week 64

One case of septum dislodgement was reported as a device deficiency in the PDS arm through week 64.

Pagoda clinical trial [NCT04108156]. Safety-evaluable population.<sup>a</sup> Frequency counts are by MedDRA Preferred Term. Multiple occurrences of the same adverse event in the same individual are counted only once per eye.<sup>b</sup> Includes cataract, cataract cortical, cataract subcapsular, and traumatic cataract. <sup>c</sup> Includes conjunctival bleb (defined as an elevation of the conjunctiva above the implant flange, which may be secondary to subconjunctival tissue thickening or transient fluid accumulation), conjunctival filtering bleb leak, conjunctival cyst, subconjunctival cyst, and implant site cyst. <sup>d</sup> Reported as "device dislocation." Case reported as a device deficiency.<sup>a</sup> Includes retinal detachment, rhegmatogenous retinal detachment.

AE, adverse event; AESI, adverse event of special interest; MedDRA, Medical Dictionary for Regulatory Activities; PDS, Port Delivery System with ranibizumab; Q4W, every 4 weeks; Q24W, every 24 weeks.

#### Majority of Patients Preferred PDS Regardless of the Number of Adverse Events Experienced Prior to Week 64



## Subgroup Analysis: Most PDS Patients Preferred PDS Regardless of Baseline Characteristics

	Preferred PDS (n = 202)	Preferred Intravitreal Injections (n = 13)	No Preference (n = 30)
Age group, n (%)			
< 65 years	136 (83.4)	11 (6.7)	16 (9.8)
65–≤ 75 years	56 (78.9)	2 (2.8)	13 (18.3)
≥ 75 years	10 (90.9)	0	1 (9.1)
Sex, n (%)			
Male	114 (80.9)	9 (6.4)	18 (12.8)
Female	88 (84.6)	4 (3.8)	12 (11.5)
Ethnicity, n (%)			
Hispanic	36 (80.0)	4 (8.9)	5 (11.1)
Non-Hispanic	164 (82.8)	9 (4.5)	25 (12.6)
Race, n (%)			
White	147 (80.8)	13 (7.1)	22 (12.1)
Black or African American	39 (86.7)	0	6 (13.3)
DR Severity, n (%)			
NPDR	191 (83.4)	9 (3.9)	29 (12.7)
PDR	10 (76.9)	3 (23.1)	0
Prior Intravitreal Injections, n (%)			
Yes	45 (86.5)	3 (5.8)	4 (7.7)
No	157 (81.3)	10 (5.2)	26 (13.5)

> 80% of Patients With DME Preferred the Continuous Delivery of Ranibizumab via PDS Over Intravitreal Injections



STRENGTH OF PREFERENCE



**CONSISTENCY OF** PREFERENCE

Among patients who preferred PDS, 97.0% reported very strong or fairly strong preference Almost three-quarters of patients cited reduction in treatment burden as the reason for preferring PDS

PDS was preferred regardless of baseline characteristics, adverse events, DR severity, and prior intravitreal treatment

These findings, driven by the patient voice, provide further evidence for PDS as a meaningful alternative intervention that could fundamentally improve outcomes in patients with retinal diseases